List of Excipients in Branded Drug NOXAFIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	ANHYDROUS DEXTROSE
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	CITRIC ACID MONOHYDRATE
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	GLYCERIN
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	POLYSORBATE 80
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	SODIUM BENZOATE
Merck Sharp & Dohme LLC	NOXAFIL	posaconazole	0085-1328	TITANIUM DIOXIDE

Noxafil Excipient Strategy and Commercial Opportunities for Posaconazole

Last updated: August 9, 2026

Noxafil is a posaconazole antifungal product with three marketed dosage forms: oral suspension, delayed-release tablets, and intravenous solution. Each uses a different excipient platform to solve a distinct delivery problem. The largest commercial opportunities are in generic and differentiated posaconazole products that improve oral absorption, reduce administration burden, simplify manufacturing, or avoid formulation-specific safety and supply constraints.

What excipients are used in Noxafil formulations?

Noxafil uses formulation-specific excipient systems rather than a single common platform. The oral suspension depends on wetting, viscosity, taste-masking, and physical-stability agents. The delayed-release tablet uses a pH-dependent release design. The intravenous formulation uses sulfobutyl ether beta-cyclodextrin sodium to solubilize posaconazole, which has very low aqueous solubility.

Noxafil dosage form	Strength	Principal excipient strategy	Commercial formulation issue
Oral suspension	40 mg/mL	Surfactant, suspending agents, buffer, preservative, antifoam, flavoring	Variable absorption and administration with food
Delayed-release tablet	100 mg	Enteric or delayed-release polymer system, compression aids, disintegrant, lubricant	Release profile and bioequivalence
Intravenous solution	18 mg/mL	Sulfobutyl ether beta-cyclodextrin sodium, pH adjustment, chelator	Cyclodextrin exposure and renal safety considerations

The FDA prescribing information identifies polysorbate 80, simethicone, sodium benzoate, sodium citrate dihydrate, citric acid monohydrate, glycerin, xanthan gum, titanium dioxide, and flavoring components in the oral suspension. The delayed-release tablet contains excipients including hypromellose acetate succinate, microcrystalline cellulose, lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, and polyethylene glycol. The injection contains sulfobutyl ether beta-cyclodextrin sodium, edetate disodium, hydrochloric acid, sodium hydroxide, and water for injection.[1]

How does posaconazole solubility determine the excipient strategy?

Posaconazole is a highly lipophilic triazole with poor aqueous solubility. Excipient selection therefore controls wetting, dissolution, supersaturation, suspension stability, and systemic exposure.

The three Noxafil dosage forms represent three different solubility solutions:

1. The oral suspension uses a dispersed system with surfactant and viscosity control.
2. The delayed-release tablet uses a solid-state and release-control approach.
3. The injection uses cyclodextrin complexation to maintain posaconazole in solution.

This creates separate product-development opportunities because a formulation that is effective for the suspension may not be suitable for the tablet or injection.

What excipients are used in Noxafil oral suspension?

The oral suspension is built around polysorbate 80 and xanthan gum. Polysorbate 80 improves wetting and dispersion of posaconazole. Xanthan gum increases viscosity and slows sedimentation. Simethicone controls foam during manufacturing and use. Sodium citrate and citric acid provide buffer capacity, while sodium benzoate supports preservation. Glycerin contributes to mouthfeel and suspension properties.

The formulation has a major clinical limitation: absorption is substantially affected by food and gastrointestinal conditions. The label directs administration with a full meal or a nutritional supplement when a full meal is not possible.[1] This creates a direct commercial opportunity for a suspension with more consistent exposure under fed and fasted conditions.

Commercial opportunities in oral suspension excipients

A differentiated suspension could target:

• Improved absorption without a high-fat meal.
• Lower viscosity for easier pouring and dose measurement.
• Reduced sedimentation and less vigorous shaking.
• Better taste masking for pediatric or long-term use.
• Lower preservative burden.
• Unit-dose packaging that reduces dosing errors.
• Compatibility with enteral feeding tubes.
• Smaller dose volume through higher drug loading.

The most valuable improvement is likely exposure consistency. A new suspension that reduces food dependence could compete on clinical convenience rather than price alone. It would need comparative pharmacokinetic evidence and careful control of particle size, crystal form, wetting, viscosity, and redispersibility.

What excipients protect Noxafil delayed-release tablets?

Noxafil delayed-release tablets use hypromellose acetate succinate, a polymer commonly used for pH-dependent release. The coating or matrix system is designed to protect the drug from early release and improve delivery beyond the stomach. The tablet also includes microcrystalline cellulose, lactose monohydrate, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.

The tablet was developed to reduce the food effect associated with the oral suspension. The FDA label permits administration with or without food, which gives the tablet a practical advantage in patients who cannot reliably consume a full meal.[1]

Formulation opportunities for delayed-release tablets

Potential generic or follow-on strategies include:

Opportunity	Development objective	Main technical barrier
Alternative enteric polymer	Match dissolution and exposure using a lower-cost or more available polymer	Demonstrating equivalent release across pH conditions
Smaller tablet	Improve swallowing and adherence	Maintaining drug loading and mechanical strength
Sprinkle or dispersible format	Address dysphagia and feeding-tube use	Preserving delayed release after manipulation
Lower-lactose formulation	Support patients with excipient sensitivity	Maintaining compression and dissolution performance
Improved moisture barrier	Extend stability in humid markets	Coating and packaging cost
Bilayer or multilayer tablet	Separate release functions or combine doses	Manufacturing complexity and regulatory burden

The tablet has the strongest commercial position among the three current dosage forms because it combines oral convenience with less dependence on meal composition. A generic tablet would face a higher formulation-development burden than a suspension, but it would also have greater potential to displace branded use.

Why is sulfobutyl ether beta-cyclodextrin important in Noxafil injection?

Noxafil injection uses sulfobutyl ether beta-cyclodextrin sodium, also known as SBECD, to improve posaconazole solubility. Cyclodextrin forms an inclusion complex with hydrophobic drug molecules and permits intravenous administration in an aqueous vehicle.

SBECD is not a passive replacement excipient. Its quantity, substitution level, impurity profile, osmolality, and renal clearance affect the product’s safety and manufacturing profile. The Noxafil label includes renal-function restrictions for the injection because the cyclodextrin component can accumulate in patients with moderate or severe renal impairment.[1]

Commercial opportunities in injectable posaconazole

The main opportunity is an injectable product with reduced cyclodextrin exposure. Potential approaches include:

• Higher drug concentration with lower total SBECD per dose.
• Alternative cyclodextrin grades or substitution levels.
• Nanocrystal or amorphous dispersion technology.
• Lipid-based or surfactant-assisted injectable systems.
• Ready-to-use bags that reduce preparation steps.
• Lower-volume presentations for fluid-restricted patients.
• Improved compatibility with hospital infusion systems.

An alternative to SBECD could create a meaningful product distinction, but it would likely require extensive chemistry, manufacturing, and controls work, together with comparative toxicology and clinical pharmacokinetic data. For a conventional generic, matching the reference formulation may be more commercially attractive than replacing the solubilizer.

How does Noxafil compare with other posaconazole products?

The key competitive distinction is not the active ingredient. It is the delivery system.

Product type	Food dependence	Administration burden	Main excipient value proposition	Competitive position
Oral suspension	High	Shake and measure; meal or supplement required	Dispersion and suspension stability	Lowest-cost entry point
Delayed-release tablet	Lower	Simple oral tablet	pH-dependent release and improved exposure consistency	Strongest oral substitution target
Intravenous solution	None for absorption	Infusion and hospital handling	Cyclodextrin solubilization	Hospital and acute-care use
Future modified suspension	Potentially lower	Liquid dosing	Improved wetting, taste, and bioavailability	Pediatric and feeding-tube opportunity
Future low-cyclodextrin injection	None for absorption	Infusion	Reduced solubilizer exposure	Renal-risk and hospital opportunity

The tablet is the most defensible commercial formulation because its excipient system addresses a known limitation of the suspension. The suspension remains attractive for lower-cost generic entry and for patients unable to swallow tablets. The injection has a narrower but clinically important opportunity linked to renal function and hospital operations.

What regulatory requirements apply to generic Noxafil excipients?

A generic posaconazole applicant must demonstrate that differences in inactive ingredients do not alter safety, efficacy, bioavailability, or product performance. The regulatory pathway depends on the dosage form.

Oral suspension

The applicant must control:

• Particle-size distribution.
• Polymorphic form and crystallinity.
• Assay uniformity throughout shelf life.
• Sedimentation and redispersibility.
• Viscosity.
• pH and preservative effectiveness.
• Dissolution or in vitro performance.
• Pharmacokinetic exposure under relevant food conditions.

A suspension with materially different excipients may require additional clinical or comparative pharmacokinetic work if the formulation changes absorption.

Delayed-release tablet

The applicant must match the reference product’s release behavior across relevant pH stages. Critical tests include:

• Acid-stage resistance.
• Buffer-stage dissolution.
• Drug release rate.
• Tablet hardness and friability.
• Moisture uptake.
• Stability after packaging.
• Fed and fasted bioequivalence.

Changing the enteric polymer, coating weight, or pore-forming system can alter exposure even when the drug content is unchanged.

Intravenous solution

The applicant must address:

• SBECD or alternative solubilizer identity.
• Complexation and solution stability.
• Particulate matter.
• Sterility and endotoxin control.
• Extractables and leachables.
• Container compatibility.
• Infusion-line compatibility.
• Renal exposure to the solubilizing excipient.

For injectable products, excipient changes generally carry greater development and regulatory risk than changes to a conventional tablet.

What patents and exclusivity issues affect Noxafil formulation opportunities?

Noxafil was first approved by the FDA in 2006 as an oral suspension. The delayed-release tablet and injection were approved later as separate dosage forms.[1] Patent and exclusivity analysis must therefore distinguish:

• Posaconazole compound claims.
• Oral suspension formulation claims.
• Delayed-release tablet claims.
• Injectable formulation claims.
• Manufacturing-process claims.
• Method-of-use claims for prophylaxis and treatment of invasive fungal infections.

The FDA Orange Book is the controlling source for listed patents and approved products. Orange Book-listed patents can create separate Paragraph IV risk for tablets, suspension, and injection products because each dosage form may have different claims and regulatory certifications.[2]

Paragraph IV exposure

A generic applicant may challenge listed patents by certifying that a patent is invalid, unenforceable, or will not be infringed. The commercial exposure depends on:

• Whether the proposed product uses the same dosage form.
• Whether the applicant adopts a carved-out indication.
• Whether the formulation falls within listed claims.
• Whether the brand holder files suit within the statutory period.
• Whether a 30-month stay applies.
• Whether settlement terms delay launch.

Excipient selection can reduce infringement risk when claims cover a specific polymer, solubilizer, particle-size range, coating architecture, or manufacturing process. A design-around strategy must be supported by claim construction and laboratory evidence. Changing an excipient does not avoid infringement if the patent claims the active ingredient, dosage form, therapeutic method, or functional result broadly.

How strong is the Noxafil formulation patent estate?

The commercial strength of the estate depends more on formulation-specific claims than on the existence of excipients in the FDA label. A patent claiming "polysorbate 80" alone may be narrow and vulnerable. A claim covering a defined composition, particle-size range, dissolution profile, stability threshold, or pharmacokinetic result can be more difficult to design around.

A practical strength assessment should score each patent family against five factors:

Factor	Strong position	Weak position
Claim scope	Covers composition and functional performance	Covers one optional excipient
Design-around difficulty	Requires changing clinical performance	Allows simple excipient substitution
Enablement	Broad data across formulations	Narrow examples only
Remaining term	Long remaining life	Near-term expiration
Litigation history	Claims survived validity challenges	Adverse claim construction or invalidity ruling

For commercial planning, formulation patents should be reviewed together with Orange Book listings, FDA approval supplements, prosecution history, and district-court litigation records. Patent numbers and expiration dates should be taken from the current Orange Book and relevant USPTO records rather than inferred from the brand label.[2,3]

Which companies are positioned to challenge Noxafil?

Competition can come from several groups:

• Generic manufacturers developing posaconazole oral suspension.
• Generic manufacturers developing delayed-release tablets.
• Hospital-focused companies developing injectable products.
• Specialty pharmaceutical companies using lipid, nanoparticle, or cyclodextrin alternatives.
• Contract development and manufacturing organizations with suspension or enteric-coating platforms.

The lowest technical barrier is an oral suspension using a formulation close to the reference product. The highest-value challenge is a tablet or modified oral formulation that preserves exposure with fewer administration restrictions. Injectable competition is more capital-intensive because sterile manufacturing and solubilizer safety must be addressed together.

What commercial opportunities exist by geography?

U.S. opportunity is driven by Orange Book patents, ANDA timing, Paragraph IV litigation, and payer substitution. European opportunity is shaped by national tendering, centralized or decentralized approval routes, hospital procurement, and local patent status. Emerging markets may favor suspension products because of price and availability, while high-income markets may favor tablets and ready-to-use injections.

Excipient sourcing is also geographic. Polysorbate 80, xanthan gum, hypromellose acetate succinate, and pharmaceutical-grade SBECD can create supplier concentration and qualification risks. A second-source strategy is commercially important for products supplied to hospitals or national procurement systems.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are:

• Controlling posaconazole particle size and solid form.
• Achieving uniform suspension dosing.
• Maintaining delayed-release performance at commercial scale.
• Managing coating variability.
• Producing a clear, sterile, injectable solution.
• Controlling SBECD quality and supply.
• Demonstrating long-term stability.
• Qualifying packaging against moisture and oxygen exposure.

The strongest opportunities for contract manufacturers are high-shear dispersion, enteric-coating scale-up, sterile fill-finish, and cyclodextrin-complex manufacturing. Companies with validated processes in these areas can reduce development time for generic or differentiated products.

What is the FDA regulatory status of Noxafil?

Noxafil is FDA-approved in oral suspension, delayed-release tablet, and injection forms for specified prophylaxis and treatment-related indications involving invasive fungal infections. The FDA label identifies important differences in administration, food effect, renal considerations, and interchangeability among dosage forms.[1]

The delayed-release tablet should not be treated as automatically interchangeable with the oral suspension solely because both contain posaconazole. Exposure, administration instructions, and release behavior differ. Product substitution must follow the applicable FDA approval and pharmacy-substitution rules.

Key Takeaways

• Noxafil uses three distinct excipient strategies because posaconazole has poor aqueous solubility.
• The oral suspension depends on polysorbate 80, xanthan gum, buffering agents, preservative, and flavoring.
• The delayed-release tablet uses hypromellose acetate succinate and related tableting and coating excipients to reduce food dependence.
• The injection uses SBECD to solubilize posaconazole, creating a renal-exposure and supply-chain consideration.
• The strongest commercial opportunity is a tablet or modified oral formulation with reliable exposure and lower administration burden.
• The fastest generic pathway is likely an oral suspension closely matching the reference product.
• The highest technical-risk opportunity is a lower-cyclodextrin or alternative-solubilizer injection.
• Excipient changes can support patent design-around strategies but do not eliminate risk from broad compound, method-of-use, or dosage-form claims.
• Current Orange Book listings, FDA approval supplements, USPTO records, and litigation dockets are required to establish live patent expiration and Paragraph IV exposure.

FAQs About Noxafil Excipient Strategy

Can polysorbate 80 be replaced in a generic posaconazole suspension?

Yes, but replacement can change wetting, particle dispersion, sedimentation, dissolution, and bioavailability. The substitute requires comparative formulation and pharmacokinetic evaluation.

Is SBECD essential for posaconazole injection?

SBECD is the solubilizer used in Noxafil injection. An alternative system may be possible, but it would require proof of solution stability, safety, sterility, compatibility, and equivalent exposure.

Which Noxafil dosage form has the greatest generic potential?

The delayed-release tablet has the strongest value proposition because it reduces the food-related administration burden of the suspension. The suspension generally presents a lower development barrier.

Can Noxafil delayed-release tablets be crushed?

Crushing can alter the delayed-release mechanism and should not be assumed to produce equivalent exposure. Product handling must follow the FDA-approved labeling or supporting product-specific evidence.

Are Noxafil excipients themselves patent-protected?

Individual excipients are generally established pharmaceutical materials. Protection may instead cover their combination with posaconazole, defined ratios, release performance, particle properties, manufacturing conditions, or therapeutic outcomes.

References

1. U.S. Food and Drug Administration. (2024). Noxafil (posaconazole) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/